ABBOTT LABORATORIES
ABT · NYSE · CIK 0000001800
SIC 2834
Pharmaceutical Preparations
Category
Chemicals
Entity
operating
Incorp.
IL
Fiscal Y/E
1231
Source: SEC EDGAR · All filings on SEC →
Investment Indicators
$82.55
-1.77 (-2.10%)
Open
$84.30
High
$84.43
Low
$81.97
Prev Close
$84.32
Volume
16,251,780
52W High
$136.28
52W Low
$84.08
50-day MA
$101.24
Quote as of: 2026-05-11
Market Cap
$146.87B
P/E
23.62
P/B
2.82
PEG
1.25
EPS
3.57
BPS
29.89
Dividend Yield
2.80%
Beta
0.65
ROE
12.51%
ROA
7.52%
Current Ratio
1.58
Gross Margin
9.92%
Operating Margin
18.17%
Net Margin
14.72%
Intrinsic Value Estimates
Multiple valuation methods, each with its own assumptions — outputs can diverge widely
Median consensus (6 methods)
$82.84B
| Method | Implied market cap | vs current |
|---|---|---|
Graham Number √(22.5 × 순이익 × 자본) | $87.48B | +68% |
Graham Formula 순이익 × (8.5 + 2 × 성장률%) | — | N/A |
Justified P/E 순이익 × 산업 평균 P/E | $97.86B | +50% |
P/B 배수 자본 × 산업 평균 P/B | $78.19B | +88% |
P/S 배수 매출 × 산업 평균 P/S | $88.66B | +66% |
DCF (Gordon) CF × (1+g) / (r − g) | $65.88B | +123% |
DDM (Gordon) D × (1+g) / (r − g) | $12.86B | +1042% |
▶ Detailed analysis — formula walk-through & scenarios
Why this conclusion
Of the 7 valuation methods, 6 were applicable. Their median fair-value lands +77.3% below the current market cap → the stock trades above most formulas' estimates (overvalued). 6 methods flag overvalued, 0 flag undervalued, the rest land within fair range. Read each formula's assumptions below before treating any single number as the answer.
Graham Number
Overvalued +67.9%√(22.5 × 순이익 × 자본)
Current
$146.87B
Implied fair
$87.48B
Gap (current − fair)
+$59.39B(+67.9%)
NetIncome = $6.52B Equity = $52.13B √(22.5 × $6.52B × $52.13B) = $87.48B
- 최대 PER 15배
- 최대 PBR 1.5배
- 안정적 흑자 기업 가정 (금융·고성장 부정확)
Graham Formula
순이익 × (8.5 + 2 × 성장률%)
Not applicable: -
Justified P/E
Overvalued +50.1%순이익 × 산업 평균 P/E
Current
$146.87B
Implied fair
$97.86B
Gap (current − fair)
+$49.01B(+50.1%)
NetIncome = $6.52B Industry P/E = 15× $6.52B × 15 = $97.86B
- 산업 평균 PER 15x 가정 (사용자 정의 가능)
- 동종 업종 비교가 핵심 — 산업별 평균 P/E 사용 권장
P/B 배수
Overvalued +87.8%자본 × 산업 평균 P/B
Current
$146.87B
Implied fair
$78.19B
Gap (current − fair)
+$68.67B(+87.8%)
Equity = $52.13B Industry P/B = 1.5× $52.13B × 1.5 = $78.19B
- 산업 평균 PBR 1.5x 가정
- 은행·보험·자산집약적 산업에 특히 유효
P/S 배수
Overvalued +65.7%매출 × 산업 평균 P/S
Current
$146.87B
Implied fair
$88.66B
Gap (current − fair)
+$58.21B(+65.7%)
Revenue = $44.33B Industry P/S = 2× $44.33B × 2 = $88.66B
- 산업 평균 PSR 2x 가정
- 매출 기반 — 적자 기업·신생 기업에 적용 가능
- 이익률 차이 무시
DCF (Gordon)
Overvalued +122.9%CF × (1+g) / (r − g)
Current
$146.87B
Implied fair
$65.88B
Gap (current − fair)
+$80.99B(+122.9%)
FCF = $7.39B Discount r = 4.0% + 5.0% = 9.0% Growth g = -2.0% $7.39B × (1 + -2.0%) / (9.0% − -2.0%) = $65.88B
- 현금흐름 입력: FCF (잉여현금흐름)
- 할인율 9.0% (무위험 4.0% + 주식위험프리미엄 5.0%)
- 영구 성장률 -2.0% (실질 GDP 수준)
DDM (Gordon)
Overvalued +1042.4%D × (1+g) / (r − g)
Current
$146.87B
Implied fair
$12.86B
Gap (current − fair)
+$134.01B(+1042.4%)
Dividend D = $1.44B Discount r = 9.0% Growth g = -2.0% $1.44B × (1 + -2.0%) / (9.0% − -2.0%) = $12.86B
- 배당 입력: 실제 지급 배당
- 할인율 9.0%
- 배당 영구 성장률 -2.0%
DCF sensitivity: discount rate × terminal growth
Each cell is the (current vs FCF × (1+g) / (r − g)) discount % under the assumed growth g and discount r.
| g \ r | 7% | 8% | 9% | 10% | 11% |
|---|---|---|---|---|---|
| 1% | +18.0% | +37.6% | +57.3% | +77.0% | +96.6% |
| 2% | -2.6% | +16.8% | +36.3% | +55.8% | +75.2% |
| 3% | -22.9% | -3.6% | +15.7% | +35.0% | +54.3% |
| 4% | -42.7% | -23.6% | -4.5% | +14.6% | +33.7% |
| 5% | -62.2% | -43.3% | -24.3% | -5.4% | +13.5% |
DDM sensitivity: discount rate × dividend growth
Each cell is the discount % vs Dividend × (1+g) / (r − g) under the assumed growth g and discount r.
| g \ r | 7% | 8% | 9% | 10% | 11% |
|---|---|---|---|---|---|
| 1% | +504.6% | +605.4% | +706.2% | +807.0% | +907.7% |
| 2% | +398.9% | +498.7% | +598.5% | +698.3% | +798.1% |
| 3% | +295.3% | +394.1% | +492.9% | +591.7% | +690.5% |
| 4% | +193.6% | +291.5% | +389.3% | +487.2% | +585.1% |
| 5% | +93.9% | +190.8% | +287.7% | +384.7% | +481.6% |
All estimates rest on strong assumptions. Treat the spread, not any single number, as the signal.
Financial Statements
In USD millions (per-share figures shown directly) · Financials as of: 2026-02-20
Income Statement
| FY | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Revenue | 44,328 | 41,950 | 40,109 | 43,653 | 43,075 |
| Cost of Revenue | 19,319 | 18,706 | 17,975 | 19,142 | 18,537 |
| Operating Income | 8,053 | 6,825 | 6,478 | 8,362 | 8,425 |
| Net Income | 6,524 | 13,402 | 5,723 | 6,933 | 7,071 |
| EPS (Basic) | 3.73 | 7.67 | 3.28 | 3.94 | 3.97 |
| EPS (Diluted) | 3.72 | 7.64 | 3.26 | 3.91 | 3.94 |
Balance Sheet
| FY | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Total Assets | 86,713 | 81,414 | 73,214 | 74,438 | 75,196 |
| Current Assets | 25,996 | 23,656 | 22,670 | 25,224 | 24,239 |
| Cash & Equivalents | 8,522 | 7,616 | 6,896 | 9,882 | 9,799 |
| Current Liabilities | 16,496 | 14,157 | 13,841 | 15,489 | 13,105 |
| Long-term Debt | 12,929 | 14,125 | 14,679 | 16,773 | 18,050 |
| Total Equity | 52,130 | 47,664 | 38,603 | 36,686 | 35,802 |
Cash Flow
| FY | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Operating CF | 9,566 | 8,558 | 7,261 | 9,581 | 10,533 |
| Investing CF | -2,422 | -2,338 | -3,133 | -1,740 | -2,008 |
| Financing CF | -6,309 | -5,404 | -7,091 | -7,636 | -5,494 |
| CapEx | 2,171 | 2,207 | 2,202 | 1,777 | 1,885 |
📄 SEC Filings
Quarterly Report
10-Q
2026-04-29
Open →
Current Report
FORM 8-K
2026-04-27
Open →
Current Report
FORM 8-K
2026-04-17
Open →
Current Report
8-K
2026-04-16
Open →
Current Report
FORM 8-K
2026-03-23
Open →
Proxy Statement
DEFINITIVE PROXY STATEMENT
2026-03-13
Open →
Current Report
FORM 8-K
2026-03-09
Open →
Current Report
FORM 8-K
2026-02-26
Open →
Current Report
FORM 8-K
2026-02-20
Open →
Annual Report
10-K
2026-02-20
Open →
Current Report
8-K
2026-01-22
Open →
Current Report
FORM 8-K
2025-12-12
Open →
Current Report
FORM 8-K
2025-11-21
Open →
Current Report
FORM 8-K
2025-11-20
Open →
Quarterly Report
10-Q
2025-10-29
Open →
Current Report
8-K
2025-10-15
Open →
Quarterly Report
10-Q
2025-07-30
Open →
Current Report
8-K
2025-07-17
Open →
Other filings (82)
Insider Transaction
xslF345X06/form4-04292026_090456.xml
2026-04-29
Open →
SCHEDULE 13G
xslSCHEDULE_13G_X02/primary_doc.xml
2026-04-29
Open →
Insider Transaction
xslF345X06/form4-04292026_120423.xml
2026-04-28
Open →
3
xslF345X06/form3-04282026_110427.xml
2026-04-28
Open →
Insider Transaction
xslF345X06/form4-04282026_110409.xml
2026-04-28
Open →
Insider Transaction
xslF345X06/form4-04282026_110450.xml
2026-04-28
Open →
Insider Transaction
xslF345X06/form4-04282026_110409.xml
2026-04-28
Open →
Insider Transaction
xslF345X06/form4-04282026_110406.xml
2026-04-28
Open →
Insider Transaction
xslF345X06/form4-04282026_110436.xml
2026-04-28
Open →
Insider Transaction
xslF345X06/form4-04282026_100441.xml
2026-04-28
Open →
Insider Transaction
xslF345X06/form4-04282026_100440.xml
2026-04-28
Open →
Insider Transaction
xslF345X06/form4-04282026_100407.xml
2026-04-28
Open →
Insider Transaction
xslF345X06/form4-04282026_100406.xml
2026-04-28
Open →
Insider Transaction
xslF345X06/form4-04282026_100459.xml
2026-04-28
Open →
Insider Transaction
xslF345X06/form4-04282026_100439.xml
2026-04-28
Open →
144
xsl144X01/primary_doc.xml
2026-04-27
Open →
Insider Transaction
xslF345X06/form4-04272026_090443.xml
2026-04-27
Open →
S-8
FORM S-8
2026-04-24
Open →
Insider Transaction
xslF345X06/form4-04022026_090447.xml
2026-04-02
Open →
Insider Transaction
xslF345X06/form4-04022026_090414.xml
2026-04-02
Open →
Insider Transaction
xslF345X06/form4-04022026_090438.xml
2026-04-02
Open →
Insider Transaction
xslF345X06/form4-04022026_090418.xml
2026-04-02
Open →
Insider Transaction
xslF345X06/form4-04022026_090445.xml
2026-04-02
Open →
SCHEDULE 13G/A
xslSCHEDULE_13G_X02/primary_doc.xml
2026-03-26
Open →
Insider Transaction
xslF345X06/form4-03252026_100352.xml
2026-03-25
Open →
3
xslF345X06/form3-03252026_100333.xml
2026-03-25
Open →
S-8
FORM S-8
2026-03-23
Open →
ARS
ANNUAL REPORT TO SECURITY HOLDERS
2026-03-13
Open →
DEFA14A
DEFINITIVE ADDITIONAL PROXY SOLICITING MATERIALS
2026-03-13
Open →
Insider Transaction
xslF345X05/form4-03042026_010300.xml
2026-03-03
Open →
Insider Transaction
xslF345X05/form4-03042026_010323.xml
2026-03-03
Open →
Insider Transaction
xslF345X05/form4-03042026_010342.xml
2026-03-03
Open →
Insider Transaction
xslF345X05/form4-03042026_010349.xml
2026-03-03
Open →
Insider Transaction
xslF345X05/form4-03042026_010311.xml
2026-03-03
Open →
Insider Transaction
xslF345X05/form4-03042026_120315.xml
2026-03-03
Open →
Insider Transaction
xslF345X05/form4-03042026_120340.xml
2026-03-03
Open →
Insider Transaction
xslF345X05/form4-03042026_120314.xml
2026-03-03
Open →
Insider Transaction
xslF345X05/form4-03042026_120334.xml
2026-03-03
Open →
Insider Transaction
xslF345X05/form4-03042026_120355.xml
2026-03-03
Open →
144
xsl144X01/primary_doc.xml
2026-03-02
Open →
144
xsl144X01/primary_doc.xml
2026-03-02
Open →
144
xsl144X01/primary_doc.xml
2026-03-02
Open →
144
xsl144X01/primary_doc.xml
2026-03-02
Open →
144
xsl144X01/primary_doc.xml
2026-03-02
Open →
144
xsl144X01/primary_doc.xml
2026-03-02
Open →
Insider Transaction
xslF345X05/form4-02272026_120249.xml
2026-02-26
Open →
Insider Transaction
xslF345X05/form4-02272026_120215.xml
2026-02-26
Open →
Insider Transaction
xslF345X05/form4-02272026_120229.xml
2026-02-26
Open →
Insider Transaction
xslF345X05/form4-02262026_110221.xml
2026-02-26
Open →
Insider Transaction
xslF345X05/form4-02262026_110230.xml
2026-02-26
Open →
Insider Transaction
xslF345X05/form4-02262026_110204.xml
2026-02-26
Open →
Insider Transaction
xslF345X05/form4-02262026_110221.xml
2026-02-26
Open →
Insider Transaction
xslF345X05/form4-02262026_110237.xml
2026-02-26
Open →
Insider Transaction
xslF345X05/form4-02262026_110256.xml
2026-02-26
Open →
Insider Transaction
xslF345X05/form4-02262026_100226.xml
2026-02-26
Open →
424B5
424B5
2026-02-25
Open →
FWP
FWP
2026-02-24
Open →
424B3
424B3
2026-02-23
Open →
S-3ASR
S-3ASR
2026-02-23
Open →
Insider Transaction
xslF345X05/form4-02062026_010212.xml
2026-02-06
Open →
Insider Transaction
xslF345X05/form4-01262026_010121.xml
2026-01-26
Open →
Insider Transaction
xslF345X05/form4-01052026_110142.xml
2026-01-05
Open →
Insider Transaction
xslF345X05/form4-01052026_110105.xml
2026-01-05
Open →
Insider Transaction
xslF345X05/form4-01052026_110137.xml
2026-01-05
Open →
Insider Transaction
xslF345X05/form4-01052026_110149.xml
2026-01-05
Open →
3
xslF345X02/form3-12242025_121230.xml
2025-12-23
Open →
3
xslF345X02/form3-12192025_091242.xml
2025-12-19
Open →
Insider Transaction
xslF345X05/form4-12122025_101232.xml
2025-12-12
Open →
SCHEDULE 13G/A
xslSCHEDULE_13G_X01/primary_doc.xml
2025-12-03
Open →
Insider Transaction
xslF345X05/form4-11252025_091124.xml
2025-11-25
Open →
144
xsl144X01/primary_doc.xml
2025-11-25
Open →
Insider Transaction
xslF345X05/form4-10022025_091040.xml
2025-10-02
Open →
Insider Transaction
xslF345X05/form4-10022025_081034.xml
2025-10-02
Open →
Insider Transaction
xslF345X05/form4-10022025_081013.xml
2025-10-02
Open →
Insider Transaction
xslF345X05/form4-10022025_081051.xml
2025-10-02
Open →
Insider Transaction
xslF345X05/form4-09032025_090946.xml
2025-09-03
Open →
Insider Transaction
xslF345X05/form4-09032025_090923.xml
2025-09-03
Open →
Insider Transaction
xslF345X05/form4-08112025_090800.xml
2025-08-11
Open →
144
xsl144X01/primary_doc.xml
2025-08-08
Open →
Insider Transaction
xslF345X05/form4-07012025_090714.xml
2025-07-01
Open →
Insider Transaction
xslF345X05/form4-07012025_090714.xml
2025-07-01
Open →
Insider Transaction
xslF345X05/form4-07012025_090745.xml
2025-07-01
Open →